...tolerated and a produced a dose-dependent immune response. In responders 24 weeks after initial vaccination, InnaVirVax...
...T cells was reduced. Data were presented at the International AIDS Society Symposium in Vancouver. InnaVirVax...
...Dec. 10, 2012). VAC-3S is in the Phase IIa IPROTECT1 trial to treat HIV-1 infection. InnaVirVax S.A....

...12 weeks or 64 µg/mL VAC-3S every 4 weeks for 3 months without maintenance vaccinations. InnaVirVax S.A....

...stage research projects. Source: BioCentury archives Companies Institutions Business area Disclosed value Purpose Diaxonhit (Euronext:ALEHT); InnaVirVax S.A....

...payments, is to respond to unsatisfied medical needs of HIV patients. Diaxonhit (Euronext:ALEHT), Paris, France InnaVirVax S.A....

...load of <=50 copies/mm 3 and a CD4+ T cell count of 200-500 cells/mm 3. InnaVirVax S.A....

...of VAC-3S given 4 weeks apart were well tolerated 4 weeks after the third injection. InnaVirVax S.A....

...French Phase I/IIa trial to evaluate VAC-3S vaccine in 24 HIV-infected patients receiving antiretroviral therapy. InnaVirVax S.A....

...lesion formation. VAC-3S is a gp41 peptide that inhibits decreases in CD4+ T cell count. InnaVirVax S.A....